Market Currents
Amgen (AMGN) is due to plead guilty today in an investigation into its business practices, the...
-
Tuesday, December 18, 2012, 4:50 AM ETAmgen (AMGN) is due to plead guilty today in an investigation into its business practices, the U.S. attorney's office says, with the NYT reporting that the company will admit to mis-branding, which usually means promoting drugs for non-approved uses. Amgen will pay a fine close to the $780M it has set aside to cover the allegations, of which $150M will be for a criminal penalty.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
